Preclinical profile of cabazitaxel

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 1851-1867

  Vrignaud, Patricia ^a   Semiond, Dorothée ^a   Benning, Veronique ^a   Beys, Eric ^a   Bouchard, Hervé ^a   Gupta, Sunil ^b  

^a SANOFI   (France)

^b Sanofi Oncology   (United States)

Author keywords

CNS tumors; mCRPC; Pediatric tumor; Taxane resistance; Xenograft; XRP6258

Indexed keywords

CABAZITAXEL; CISPLATIN; DOCETAXEL; GEMCITABINE; MITOXANTRONE; PACLITAXEL; PREDNISOLONE; PREDNISONE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; TAXOID;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; COLON ADENOCARCINOMA; DIARRHEA; DOCETAXEL SENSITIVE MODEL; DRUG ABSORPTION; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESISTANCE; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; HUMAN; HYPERTRANSAMINASEMIA; IN VITRO STUDY; IN VIVO STUDY; LEUKOPENIA; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MELANOMA B16; MICROTUBULE STABILIZATION; MOLECULAR DYNAMICS; MONOTHERAPY; MOTOR NEUROPATHY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; SARCOMA; SENSORY NEUROPATHY; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; CONFORMATION; DRUG EFFECTS; METABOLISM; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR CONFORMATION; NEOPLASMS; TAXOIDS;

EID: 84908073480     PISSN: 11778881     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S64940     Document Type: Article

References (82)

1. No authors listed. FDA approves treatment IND protocol for taxol. Clin Pharm. 1992;11:912.
2. Label and Approval History - Taxol [webpage on the Internet]. Silver Spring: US Food and Drug Administration; 2011. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=020262&DrugName=TAXOL&ActiveIngred=PACLITAXEL&SponsorApplicant=HQ%20SPCLT%20PHARMA&ProductMktStatus=1&goto=Search.Label_ApprovalHistory. Accessed July 29, 2014.
3. Sanofi U.S.LLC. TAXOTERE® (Docetaxel) Injection Concentrate, Intravenous Infusion (IV) Prescribing Information 2013; USA. Bridgewater: Sanofi U.S.LLC; 2013. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020449s071lbl.pdf. Accessed July 29, 2014.
4. Mead Johnson Oncology Products. TAXOL® (Paclitaxel) Injection. Princeton: Bristol-Meyers Squibb Company; 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf. Accessed July 29, 2014.
5. Chien AJ, Moasser MM. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol. 2008;35:S1-S14.
6. Fojo AT, Menefee M. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Semin Oncol. 2005;32:S3-S8.
7. Perez EA. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther. 2009;8:2086-2095.
8. O'Neill AJ, Prencipe M, Dowling C, et al. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer. 2011;10:126.
9. Bouchard H, Semiond D, Risse ML, Vrignaud P. Novel taxanes: Cabazitaxel case study. In: Fischer J, Ganellin CR, Rotella DP, editors. Analogue-Based Drug Discovery III, first edition.Weinheim, Germany. Wiley-VCH Verlag GmbH & Co. KGaA, 2013;13:319-341.
10. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147-1154.
11. Sanofi. JEVTANA® (Cabazitaxel) Injection, Summary of Product Characteristics. Bridgewater: Sanofi; 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002018/WC500104764.pdf. Accessed July 29, 2014.
12. Sanofi U.S.LLC. JEVTANA® (Cabazitaxel) Injection, Prescribing Information, FDA. Bridgewater: Sanofi U.S.LLC; 2013. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201023s003lbl.pdf. Accessed July 29, 2014.
13. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents. 2002;2: 1-17.
14. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253-265.
15. Nogales E. Structural insight into microtubule function. Annu Rev Biophys Biomol Struct. 2001;30:397-420.
16. Giannakakou P, Poy G, Zhan Z, et al. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene. 2000;19:3078-3085.
17. Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest. 1997;100:1282-1293.
18. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008;1785:96-132.
19. Modi S, DiGiovanna MP, Lu Z, et al. Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Invest. 2005;23:483-487.
20. ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 [webpage on the Internet]. Bethesda: NCBI; 2014. Available from: http://www.ncbi.nlm.nih.gov/gene/5243.
21. Nightingale G, Ryu J. Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer. P T. 2012;37:440-448.
22. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr. 1993;(15):55-61.
23. Yin S, Bhattacharya R, Cabral F. Human mutations that confer paclitaxel resistance. Mol Cancer Ther. 2010;9:327-335.
24. Vrignaud P, Sémiond D, Lejeune P, et al. Preclinical antitumor activity of cabazitaxel, a semi-synthetic taxane active in taxane-resistant tumors. Clin Cancer Res. 2013;19:2973-2983.
25. Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P, André S. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol. 1995;22: 3-16.
26. Denis JN, Greene AE, Guenard D, Gueritte-Voegelein F, Mangatal L, Potier P. Highly efficient, practical approach to natural taxol. J Am Chem Soc. 1988;110:5917-5919.
27. Holton RA, Somoza C, Kim H-B, et al. First total synthesis of Taxol. 1. Functionalization of the B ring. J Am Chem Soc. 1994;116: 1597-1598.
28. Sanofi U.S.LLC. Taxotere® Material Safety Data Sheet. Bridgewater: Sanofi U.S.LLC; 2010. Available from: http://bdipharma.com/MSDS/Sanofi-Aventis/Taxotere%208-10.pdf. Accessed July 29, 2014.
29. Roche VF. Cancer and chemotherapy. In: Lemke TL, Williams DA, Roche VF, Zito SW, editors. Foye's Principles of Medicinal Chemistry, seventh edition. Baltimore, MD: Lippincott Williams, Wilkins, 2013;37:1199-1266.
30. Montaudon D, Vrignaud P, Londos-Gagliardi D, Robert J. Fluorescence anisotropy of cell membranes of doxorubicin-sensitive and -resistant rodent tumoral cells. Cancer Res. 1986;46:5602-5605.
31. Azarenko O, Smiyun G, Mah J, Wilson L, Jordan MA. Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells. Mol Cancer Ther. 2014;13:2092-2103.
32. Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther. 2011;5:117-124.
33. Semiond D, Sidhu SS, Bissery M-C, Vrignaud P. Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel. Cancer Chemother Pharmacol. 2013;72:515-528.
34. Ridoux L, Semiond D, Vincent C, et al. A Phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors. Anticancer Drugs. Submitted March 2014.
35. Darshan MS, Loftus MS, Thadani-Mulero M, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 2011;71: 6019-6029.
36. Gan L, Chen S, Wang Y, et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res. 2009;69:8386-8394.
37. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010;70:7992-8002.
38. Bourre L, Nicolle D, Legrier M-E, et al. Evaluation of the response to cabazitaxel of a docetaxel-responsive hormone-refractory prostate tumor xenograft model (HID28). In: American Society of Clinical Oncology Annual Meeting; June 1-5, 2012; Chicago, Illinois. Abstract e15161.
39. Chamberlain MC, Kormanik P. Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol. 1995;13:2066-2071.
40. Chamberlain MC, Kormanik P. Salvage chemotherapy with taxol for recurrent anaplastic astrocytomas. J Neurooncol. 1999;43:71-78.
41. Forsyth P, Cairncross G, Stewart D, Goodyear M, Wainman N, Eisenhauer E. Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs. 1996;14:203-206.
42. Hurwitz CA, Strauss LC, Kepner J, et al. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. J Pediatr Hematol Oncol. 2001;23:277-281.
43. Prados MD, Schold SC, Spence AM, et al. Phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin Oncol. 1996;14: 2316-2321.
44. Deeken JF, Loscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 2007;13:1663-1674.
45. Fellner S, Bauer B, Miller DS, et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 2002;110:1309-1318.
46. Kemper EM, Verheij M, Boogerd W, Beijnen JH, van Tellingen O. Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. Eur J Cancer. 2004;40:1269-1274.
47. Cisternino S, Bourasset F, Archimbaud Y, Sémiond D, Sanderink G, Scherrmann JM. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br J Pharmacol. 2003;138:1367-1375.
48. Izbicka E, Campos D, Marty J, Carrizales G, Mangold G, Tolcher A. Molecular determinants of differential sensitivity to docetaxel and paclitaxel in human pediatric cancer models. Anticancer Res. 2006;26: 1983-1988.
49. Blaney SM, Seibel NL, O'Brien M, et al. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol. 1997;15:1538-1543.
50. Hurwitz CA, Relling MV, Weitman SD, et al. Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study. J Clin Oncol. 1993;11:2324-2329.
51. Mora J, Cruz CO, Parareda A, de Torres C. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol. 2009;31:723-729.
52. Zwerdling T, Krailo M, Monteleone P, et al. Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children's Oncology Group. Cancer. 2006;106:1821-1828.
53. Clinicaltrials.gov [webpage on the Internet]. Cabazitaxel in pediatric and central nervous system tumors. Bethesda: National Institutes of Health; 2014. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01751308. Accessed July 29, 2014.
54. Lorch JH, Goloubeva O, Haddad RI, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011;12:153-159.
55. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991-4997.
56. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92:699-708.
57. Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol. 2002;13:1539-1549.
58. Sanofi U.S.LLC. TAXOTERE® (Docetaxel) Injection Concentrate, Intravenous Infusion (IV) Prescribing Information. Bridgewater: Sanofi U.S.LLC; 2010. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020449s059lbl.pdf. Accessed May 2014.
59. Vrignaud P. Therapeutic synergism of cabazitaxel in combination with cisplatin in tumor-bearing mice. In: American Association for Cancer Research Annual Meeting; April 2-6, 2011; Orlando, Florida. Abstract 2522.
60. Lockhart AC, Sundaram S, Sarantopoulos J, et al. Phase I trial of cabazitaxel plus cisplatin in patients with advanced solid tumors. Poster 162 presented at: Genitourinary Cancers Symposium; February 2-4, 2012; San Francisco, California.
61. Rixe O, Puzanov I, LoRusso PM, et al. Dose-escalation Phase I study of cabazitaxel (Cbz) + gemcitabine (Gem) in patients (pts) with metastatic or unresectable advanced solid malignancy. Poster 497P presented at: European Society of Medical Oncology Congress; Sept 28 - Oct 2, 2012; Vienna.
62. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs. 1995;6:339-8.
63. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990;82: 1247-1259.
64. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol. 2006;24:3657-3663.
65. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005;23:5542-5551.
66. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18:2354-2362.
67. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23: 7794-7803.
68. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357: 2666-2676.
69. Winer EP, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. 2004;22:2061-2068.
70. Gokhale PC, Newsome JT, Dritschilo A, et al. Toxicity, histopathologic and pharmacokinetic evaluation of liposome-encapsulated paclitaxel and Taxol in mice and rabbits. Poster 2759 presented at: American Association for Cancer Research Annual Meeting; April 10-14, 1999; Philadelphia, Pennsylvania.
71. Tinwell H, Ashby J. Genetic toxicity and potential carcinogenicity of taxol. Carcinogenesis. 1994;15:1499-1501.
72. Diéras V, Lortholary A, Laurence V, et al. Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study. Eur J Cancer. 2013;49:25-34.
73. Fumoleau P, Trigo JM, Isambert N, Sémiond D, Gupta S, Campone M. Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours. BMC Cancer. 2013;13:460.
74. Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15:723-730.
75. Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h iv infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol. 2008;19: 1547-1552.
76. Villanueva C, Awada A, Campone M, et al. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. Eur J Cancer. 2011;47:1037-1045.
77. Villanueva C, Awada A, Campone M, et al. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. Eur J Cancer. 2011;47(7):1037-1045.
78. Ferron GM, Dai Y, Semiond D. Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013;71:681-692.
79. Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm. 1996;24:153-172.
80. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet. 1999;36:99-114.
81. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187-3205.
82. Malik Z, Di Lorenzo G, Ardavanis A, et al. Updated safety results from a cohort compassionate-use programme (CUP) and early access programme (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D). Eur J Cancer. 2013;49(Supplement 2):S1-S1028:abstract 2902.